8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
Published . Updated .
Key takeaways
- 8-K - Perspective Therapeutics filed an 8-K with the SEC on Nov 6 (a notice of a material company event).
- Exposed: CATX
- Market reaction: CATX +6.9% on the day
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Perspective Therapeutics filed an 8-K with the SEC on Nov 6 (a notice of a material company event).
Directly affected
- CATX Perspective Therapeutics-71.0% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Perspective Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+15.5% 30d
Eli Lilly and is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.1% 30d
Johnson & Johnson is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+9.0% 30d
AbbVie is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.3% 30d
Abbott Laboratories is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CATX | +43.73% | +11.66% | base | +6.86% | after close | after close | after close |
| XLV | -0.05% | -0.52% | base | -0.06% | after close | after close | after close |
| LLY | +3.64% | +3.08% | base | -0.91% | after close | after close | after close |
| JNJ | +0.29% | -2.31% | base | +1.42% | after close | after close | after close |
| ABBV | +2.38% | -0.72% | base | +1.24% | after close | after close | after close |
| MRK | +1.80% | -1.52% | base | -0.09% | after close | after close | after close |
| ABT | -6.44% | -3.65% | base | -3.14% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-06 AccNo: 0001193125-26-450709 Size: 17 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Perspective Therapeutics (CATX)
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | +1.24% | final price |
| ABBV | three days earlier | -0.72% | final price |
| ABBV | five days earlier | +2.38% | final price |
| ABT | that day | -3.14% | final price |
| ABT | three days earlier | -3.65% | final price |
| ABT | five days earlier | -6.44% | final price |
| Perspective Therapeutics (CATX) | that day | +6.86% | final price |
| Perspective Therapeutics (CATX) | three days earlier | +11.66% | final price |
| Perspective Therapeutics (CATX) | five days earlier | +43.73% | final price |
| JNJ | that day | +1.42% | final price |
| JNJ | three days earlier | -2.31% | final price |
| JNJ | five days earlier | +0.29% | final price |
| LLY | that day | -0.91% | final price |
| LLY | three days earlier | +3.08% | final price |
| LLY | five days earlier | +3.64% | final price |
| MRK | that day | -0.09% | final price |
| MRK | three days earlier | -1.52% | final price |
| MRK | five days earlier | +1.80% | final price |
| XLV | that day | -0.06% | final price |
| XLV | three days earlier | -0.52% | final price |
| XLV | five days earlier | -0.05% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 37 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 59 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 53 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 43 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 79 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 35 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 49 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 50 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Perspective Therapeutics (CATX)
Companies mentioned with this story
- CATX Perspective Therapeutics
For “8-K - Perspective Therapeutics, Inc. (0000728387) (Filer),” Perspective Therapeutics (CATX) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> CATX
How “8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)” reaches Perspective Therapeutics (CATX)
“8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)” (6 Nov 2026) reaches Perspective Therapeutics (CATX) through this story.
What ties Perspective Therapeutics (CATX) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> CATX
Dates and price levels for Perspective Therapeutics (CATX)
CATX traded between 0.78 and 2.75 across 20 sessions. The latest close on file is 0.79.
How strong the case is around Perspective Therapeutics (CATX)
14 out of 100
“8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.